Nile Therapeutics, Inc. (Nile) is a development-stage biopharmaceutical company in the business of commercially developing products for the treatment of cardiovascular diseases. The Company’s product CD-NP, a chimeric natriuretic peptide is in Phase II clinical studies for the treatment of heart failure. The Company is developing CD-NP for an initial indication of acute decompensated heart failure (ADHF). The Company is also developing CU-NP, a pre-clinical rationally designed natriuretic peptide that consists of amino acid chains identical to those produced by the human body, specifically the ring structure of C-type natriuretic peptide (CNP), and the N- and C-termini of Urodilatin (URO).